Innovation in Therapies CSL Behring continues to expand its product portfolio with new launches such as the 10g prefilled syringe for Hizentra, indicating ongoing growth and innovation in biotherapeutics that can be leveraged for upselling or new application opportunities.

Digital Engagement Enhancement Recent partnerships with digital platform providers like ON24 highlight CSL Behring's focus on integrating advanced digital engagement tools, creating opportunities for sales teams to offer digital marketing and customer engagement solutions.

Sustainability Leadership The appointment of a Chief Sustainability Officer and active sustainability initiatives demonstrate CSL Behring’s commitment to environmental responsibility, opening avenues for eco-friendly product solutions and sustainability-related collaborations.

Manufacturing Investments Major capital investments such as the over $800 million infusion into the influenza vaccine plant showcase the company’s focus on expanding manufacturing capacity, which presents potential for supply chain partnerships and technology upgrades.

Strategic Partnerships Collaborations with organizations like Rare Disorders, Inc. and Clever Culture Systems suggest CSL Behring's openness to innovative partnerships, providing opportunities to align with niche healthcare organizations and biotech innovators.